1 Introduction
This document is a supplement to the Queensland Clinical Guideline (QCG) Hypoglycaemia–newborn. It provides supplementary information regarding guideline development, makes summary recommendations, suggests measures to assist implementation and quality activities and summarises changes (if any) to the guideline since original publication. Refer to the guideline for abbreviations, acronyms, flow charts and acknowledgements.

1.1 Funding
The development of this guideline was funded by Healthcare Improvement Unit, Queensland Health. Consumer representatives were paid a standard fee. Other working party members participated on a voluntary basis.

1.2 Conflict of interest
Declarations of conflict of interest were sought from working party members as per the Queensland Clinical Guidelines Conflict of Interest statement. No conflict of interest was identified.

1.3 Development process
This version of the guideline followed the QCG Full review process.
1.4 Summary of changes

Queensland clinical guidelines are reviewed every 5 years or earlier if significant new evidence emerges. Table 1 provides a summary of changes made to the guidelines since original publication.

Table 1. Summary of change

<table>
<thead>
<tr>
<th>Publication date</th>
<th>Identifier</th>
<th>Summary of major change</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 2010</td>
<td>M1002.8-V1-R12</td>
<td>• First publication</td>
</tr>
<tr>
<td>August 2011</td>
<td>MN10.8-V2-R12</td>
<td>• New website. Name and format changes</td>
</tr>
</tbody>
</table>
| July 2012        | MN10.8-V3-R12  | • Hydrochlorothiazide dose corrected  
|                  |             | • Reference to Neofax added |
| August 2013      | MN13.8-V4-R18  | • First review of key amendments:  
|                  |             |   o Name of guideline changed from Neonatal hypoglycaemia and blood glucose monitoring to Newborn hypoglycaemia  
|                  |             |   o BGL monitoring recommendations  
|                  |             |   o Definition of severe hypoglycaemia  
|                  |             |   o Addition of flow charts  
|                  |             |   o Supplement published |
| June 2015        | MN13.8-V5-R18  | • Amendment: indications for the option of using glucose gel 10% included  
|                  |             | • Author changed to Queensland Clinical Guidelines  
|                  |             | • Front cover updated |
| September 2019   | MN19.8-V11-R24 | • Full review  
| QCG Steering Committee |             | • Additional information added about:  
| Statewide Maternity and Neonatal Clinical Network (QLD) |             |   o Use of glucose gel 40% and presentation of medication  
|                  |             |   o Calculation and preparation of glucose concentrations for IV administration  
|                  |             |   o Use of glucagon early in treatment  
|                  |             |   o Reference to NeoMedQ monographs for medication doses and other information  
|                  |             |   o BGL levels for baby greater than 24 hours and when to cease monitoring  
|                  |             | • Addition of nurse practitioner to review baby  
|                  |             | • Investigations prioritised  
|                  |             | • Information added about six hour fast test  
|                  |             | • Flowcharts separated into 3 levels of care-screening, BGL1.5 mmol/L–2.5 mmol/L and BGL less than 1.5 mmol/L |
### Summary of major change

<table>
<thead>
<tr>
<th>Publication date</th>
<th>Identifier</th>
<th>Summary of major change</th>
</tr>
</thead>
</table>
| **October 2019** | MN19.8-V11-R24 | • Amendments  
  o Flowchart: Risk factors in Preventative care of the well at risk (for hypoglycaemia) newborn baby  
  Meconium stained liquor to meconium aspiration syndrome  
  • Table 2 Maternal risk factors  
  o Maternal medications—Terbutaline  
    ▪ Words added *as tocolysis within previous 48 hours*  
  o Maternal conditions—Maternal pre-eclampsia/eclampsia or hypertension or other conditions causing placental insufficiency  
    ▪ Words added *from any cause*  
    ▪ Reference amended |
| **March 2021** | MN19.8-V11-R24 | • Amendment: 3.1 Screening and assessment of at risk baby (asymptomatic) Table 5 Screening  
  o **From:** If glucometer BGL is less than or equal to 2 mmol/L, confirmation by a validated diagnostic testing method is recommended  
  o **To:** If glucometer BGL is less than or equal to 2 mmol/L, confirmation by a validated diagnostic testing method is essential and urgent  
  • Amendment: Supplement: Table 10. Clinical quality measures  
  o **From:** Number of glucometer screenings less than 2 mmol/L confirmed by validated test  
  o **To:** Number of glucometer screenings less than 2.6 mmol/L confirmed by validated test |
| **June 2021** | MN19.8-V11-R24 | • Flowchart 1 Preventative care of the well at risk (for hypoglycaemia) newborn baby  
  o **Added:** Consult with neonatologist if baby is symptomatic, unwell or BGL is less than 1.5 mmol/L  
  • Flowchart 3 Management of neonatal hypoglycaemia (baby symptomatic or BGL < 1.5 mmol/L)  
  o **From:** Consult with neonatologist if IV glucose > 10 mg/kg/minute or baby > 48 hours or BGL is difficult to control  
  o **To:** Consult with paediatrician or neonatologist if IV glucose > 8 mg/kg/minute or baby 48 hours or BGL is difficult or requires medication to control  
  • Section 4.4.1 BGL monitoring Table 11 BGL measurement **added:**  
  o Consult with a paediatrician or neonatologist if at any time the BGL is:  
    ▪ Less than 2.6 mmol/L more than three times or  
    ▪ Less than 1.6 mmol/L more than two times  
    ▪ Refer to Table 19 Ongoing long term management  
  • Section 4.5 Intravenous glucose Table 13 IV fluids  
  o **From:** Discuss baby’s management with neonatologist via RSQ if glucagon or hydrocortisone is required:  
  o **To:** Discuss baby’s management with neonatologist via RSQ if glucagon or hydrocortisone, or other medication is required |
<p>| <strong>September 2021</strong> | MN19.8-V11-R24 | • Flowchart 1 Preventative care of the well at risk (for hypoglycaemia) newborn baby replaced with correct version |</p>
<table>
<thead>
<tr>
<th>Publication date</th>
<th>Identifier</th>
<th>Summary of major change</th>
</tr>
</thead>
</table>
| March 2022      | MN19.8-V11-R24   | - Flowchart 3 Management of neonatal hypoglycaemia (baby symptomatic or BGL < 1.5 mmol/L)  
- **From:** Urgent treatment–administer glucagon and then IV 10% glucose  
  o Give glucagon IM or subcut if IV access delayed by more than 10 minutes  
- **To:** Urgent treatment–  
  o If asymptomatic or mild symptoms:  
    - Administer IV 10% glucose bolus  
    - Consider glucose gel 40% and breastfeed in addition  
    - Commence 10% glucose infusion at 60 mL/kg  
  o Give glucagon IM or subcut if IV access delayed by more than 15 minutes  
  o If symptomatic or BGL not improving:  
    - Give glucagon IV (IM or subcut if IV access delayed by more than 15 minutes)  
    - Commence 10% glucose infusion at 80 mL/kg  
- Section 4.2 Initial management (first 48 hours of life): Table 8  
  o BGL less than 1.5 mmol/L or unrecordable–reworded to urgently give IV glucose bolus and commence 10% glucose infusion  
- Section 4.5.1 Regimen for glucose infusion  
  o If asymptomatic/mild symptoms commence 10% glucose at 60 mL/kg  
  o If symptomatic or BGL not improving commence 10% glucose at 80 mL/kg |
| June 2022       | MN19.8-V12-R24   | - Amendment Flowchart 3: Management of neonatal hypoglycaemia (baby symptomatic or BGL < 1.5 mmol/L)  
  o Renamed **TO** Management of BGL less than 1.5 mmol/L or baby symptomatic  
  o Amended to align with document text: Criteria for commencement of weaning IV therapy **FROM** BGL 2.6 mmol/L for more than 12 hours **TO** BGL 3.0 mmol/L for more than 12 hours. Duplicate label on outflow amended **FROM** yes **TO** no  
  o Amended Urgent treatment  
  **FROM** If asymptomatic or mild symptoms:  
    - Administer IV 10% glucose bolus  
    - Consider glucose gel 40% and breastfeed in addition  
    - Commence 10% glucose infusion at 60 mL/kg  
  **TO** Commence 10% glucose infusion at 60 mL/kg/day  
  **FROM** If symptomatic or BGL not improving:  
    - Give glucagon IV (IM or subcut if IV access delayed by more than 15 minutes)  
    - Commence 10% glucose infusion at 80 mL/kg  
  **TO** Commence 10% glucose infusion at 60 mL/kg/day  
  o Give 10% glucose 1–2 mL/kg IV bolus  
  o Consider glucose gel 40% and breastfeed  
  o Recheck BGL after 30 minutes  
  o If BGL improving, continue 10% glucose IV adjust as needed |
If symptomatic or BGL not improving
- Give glucagon IV
- Repeat BGL after 30 minutes and if required, repeat glucose bolus and glucagon

If IV access delayed > 15 minutes give glucagon IM or subcut

- Added to Definitions: enteral feeding

- Table 5 Screening: Last row split into two rows (new row: Validate BGL less than 2.6 mmol/L) no content change

- Table 8: Initial management (first 48 hours of life)
  - References to NeoMedQ monographs rationalised to top of page
  - Third row (BGL less than 1.5 mmol/L or unrecordable) split into two rows (new row Difficult IV access) no content change
  - Last row: (Ceasing BGL monitoring) moved to new table: Ceasing BGL monitoring

- Table 11: BGL monitoring
  - First row (BGL) split into 5 rows (no content change)
  - Last row (Ceasing BGL monitoring) moved to new table: Ceasing BGL monitoring

- Table 12: Ceasing BGL monitoring
  - New table from content in Table 8 and Table 11
  - Correction to criteria for ceasing after 48 hours FROM 3 mmol/L TO 3.3 mmol/L

- Subsequent table numbering increased by 1

- Table 15: Medications
  - References updated to relevant NeoMedQ medicine monographs only
  - Minor formatting corrections throughout
2 Methodology

Queensland Clinical Guidelines (QCG) follows a rigorous process of guideline development. This process was endorsed by the Queensland Health Patient Safety and Quality Executive Committee in December 2009. The guidelines are best described as ‘evidence informed consensus guidelines’ and draw from the evidence base of existing national and international guidelines and the expert opinion of the working party.

2.1 Topic identification

The topic was identified as a priority by the Statewide Maternity and Neonatal Clinical Network at a forum in 2009.

2.2 Scope

The scope of the guideline was determined using the following framework.

Table 2. Scope framework

<table>
<thead>
<tr>
<th>Scope framework</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Newborn babies from birth up to 28 days of age</td>
</tr>
<tr>
<td>Purpose</td>
<td>Identify relevant evidence related to:</td>
</tr>
<tr>
<td></td>
<td>• Screening, prevention, assessment and management of hypoglycaemia</td>
</tr>
<tr>
<td>Outcome</td>
<td>Support:</td>
</tr>
<tr>
<td></td>
<td>• Prevention of hypoglycaemia in at risk babies</td>
</tr>
<tr>
<td></td>
<td>• Early identification of hypoglycaemia</td>
</tr>
<tr>
<td></td>
<td>• Accurate and assessment of hypoglycaemia</td>
</tr>
<tr>
<td></td>
<td>• Best practice management</td>
</tr>
<tr>
<td></td>
<td>• Reduce the risk of sequelae</td>
</tr>
<tr>
<td>Exclusions</td>
<td>• Ongoing management of metabolic disorders (e.g. hyperinsulinaemia, galactosaemia)</td>
</tr>
<tr>
<td></td>
<td>• Management of sequelae of hypoglycaemia (e.g. neurological; impairment)</td>
</tr>
</tbody>
</table>

2.3 Clinical questions

The following clinical questions were generated to inform the guideline scope and purpose:

- How is neonatal hypoglycaemia defined and described?
- What babies are at risk of hypoglycaemia?
- What preventative measures reduce risk or limit progression of hypoglycaemia (is any)?
- What is considered best practice with regard to identification of hypoglycaemia?
- What are the causes, investigations and initial management of severe, persistent, recurrent or atypical hypoglycaemia?
- What parent information and discharge planning is required?
2.4 Search strategy
A search of the literature was conducted during March–April 2018. The QCG search strategy is an iterative process that is repeated and amended as guideline development occurs (e.g. if additional areas of interest emerge, areas of contention requiring more extensive review are identified or new evidence is identified). All guidelines are developed using a basic search strategy. This involves both a formal and informal approach.

Table 3. Basic search strategy

<table>
<thead>
<tr>
<th>Step</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| 1. Review clinical guidelines developed by other reputable groups relevant to the clinical speciality | • This may include national and/or international guideline writers, professional organisations, government organisations, state-based groups.  
• This assists the guideline writer to identify:  
  o The scope and breadth of what others have found useful for clinicians and informs the scope and clinical question development  
  o Identify resources commonly found in guidelines such as flowcharts, audit criteria and levels of evidence  
  o Identify common search and key terms  
  o Identify common and key references |
| 2. Undertake a foundation search using key search terms | • Construct a search using common search and key terms identified during Step 1 above  
• Search the following databases  
  o PubMed  
  o CINAHL  
  o Medline  
  o Cochrane Central Register of Controlled Trials  
  o EBSCO  
  o Embase  
• Studies published in English less than or equal to 5 years previous are reviewed in the first instance. Other years may be searched as are relevant to the topic  
• Save and document the search  
• Add other databases as relevant to the clinical area |
| 3. Develop search word list for each clinical question | • This may require the development of clinical sub-questions beyond those identified in the initial scope.  
• Using the foundation search performed at Step 2 as the baseline search framework, refine the search using the specific terms developed for the clinical question  
• Save and document the search strategy undertaken for each clinical question |
| 4. Other search strategies | • Search the reference lists of reports and articles for additional studies  
• Access other sources for relevant literature  
  o Known resource sites  
  o Internet search engines  
  o Relevant text books |

2.4.1 Keywords
The following keywords were used in the basic search strategy: newborn, neonatal, infant, baby, low birth weight, hypoglycaemia, glycogen, neurological, breastfeeding, glucose gel, dextrose gel, hyperinsulinaemia. Other keywords may have been used for specific aspects of the guideline.
2.5 Consultation

Major consultative and development processes occurred between April 2018 and May 2019. These are outlined in Table 4.

Table 4. Major guideline development processes

<table>
<thead>
<tr>
<th>Process</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical lead</td>
<td>• The nominated co-clinical leads were approved by QCG Steering Committee</td>
</tr>
<tr>
<td>Consumer participation</td>
<td>• Consumer participation was invited from a range of consumer-focused organisations who had previously accepted an invitation for on-going involvement with QCG</td>
</tr>
</tbody>
</table>
| Working party         | • An EOI for working party membership was distributed via email to Queensland clinicians and stakeholders in February 2019  
                       | • The working party was recruited from responses received  
                       | • Working party members who participated in the working party consultation processes are acknowledged in the guideline  
                       | • Working party consultation occurred in a virtual group via email                                                                             |
| Statewide consultation| • Consultation was invited from Queensland clinicians and stakeholders during February 2019–May 2019  
                       | • Feedback was received primarily via email  
                       | • All feedback was compiled and provided to the clinical lead and working party members for review and comment |

2.6 Endorsement

The guideline was endorsed by the:

- Queensland Clinical Guidelines Steering Committee in August 2019

2.7 Citation

The recommended citation of Queensland Clinical Guidelines is in the following format:


EXAMPLE:
3 Levels of evidence

The levels of evidence identified or used by the GRADE Working Group were used to inform the summary recommendations. Levels of evidence are outlined in Table 5. Levels of evidence (NHMRC), Table 6. Levels of evidence (Up-to-date®) and Table 7. Levels of evidence (GRADE).

Note that the ‘consensus’ definition* in Table 5. Levels of evidence (NHMRC) is different from that proposed by the NHMRC. Instead, it relates to forms of evidence that are not identified by the NHMRC and/or that arise from the clinical experience of the guideline’s clinical lead and working party.

Summary recommendations are outlined in Table 8. Summary recommendations.

Table 5. Levels of evidence (NHMRC)

<table>
<thead>
<tr>
<th>Levels of evidence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence obtained from a systematic review of all relevant randomised controlled trials.</td>
</tr>
<tr>
<td>II</td>
<td>Evidence obtained from at least one properly designed randomised controlled trial.</td>
</tr>
<tr>
<td>III-1</td>
<td>Evidence obtained from well-designed pseudo randomised controlled trials (alternate allocation or some other method).</td>
</tr>
<tr>
<td>III-2</td>
<td>Evidence obtained from comparative studies including systematic review of such studies with concurrent controls and allocation not randomised (cohort studies), case control studies or interrupted time series with a control group.</td>
</tr>
<tr>
<td>III-3</td>
<td>Evidence obtained from comparative studies with historical control, two or more single arm studies, or interrupted time series without parallel control group.</td>
</tr>
<tr>
<td>IV</td>
<td>Evidence obtained from case series, either post-test or pre-test and post-test.</td>
</tr>
<tr>
<td>Consensus*</td>
<td>Opinions based on respected authorities, descriptive studies or reports of expert committees or clinical experience of the working party.</td>
</tr>
</tbody>
</table>

Table 6. Levels of evidence (Up-to-date®)

<table>
<thead>
<tr>
<th>Recommendation grades</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form</td>
</tr>
<tr>
<td>B</td>
<td>Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form</td>
</tr>
<tr>
<td>C</td>
<td>Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence grades</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
</tbody>
</table>
Table 7. Levels of evidence (GRADE)

<table>
<thead>
<tr>
<th>Grades of evidence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>High quality</td>
<td>We are very confident that the true effect lies close to that of the estimate of the effect</td>
</tr>
<tr>
<td>Moderate quality</td>
<td>We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different</td>
</tr>
<tr>
<td>Low quality:</td>
<td>Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect</td>
</tr>
<tr>
<td>Very low quality:</td>
<td>We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect</td>
</tr>
<tr>
<td>Quality of evidence</td>
<td></td>
</tr>
<tr>
<td>4+</td>
<td>High</td>
</tr>
<tr>
<td>3+</td>
<td>Moderate</td>
</tr>
<tr>
<td>2+</td>
<td>Low</td>
</tr>
<tr>
<td>1+</td>
<td>Very low</td>
</tr>
</tbody>
</table>

### 3.1 Summary recommendations

Summary recommendations and levels of evidence are outlined in Table 5.

Table 8. Summary recommendations

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grading of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Screen babies at risk of hypoglycaemia</td>
</tr>
<tr>
<td>2</td>
<td>Do not screen healthy asymptomatic term babies</td>
</tr>
<tr>
<td>3</td>
<td>Administer glucose gel 40% and breastfeed babies with BGL 1.5mmol/L–2.5 mmol/L</td>
</tr>
<tr>
<td>4</td>
<td>Perform six hour fast test for babies with history of clinically significant hypoglycaemia, suggestion of congenital hypoglycaemia, or family history of hypoglycaemia</td>
</tr>
<tr>
<td>5</td>
<td>Confirm glucometer BGL less than 2.6 mmol/L by validated test</td>
</tr>
</tbody>
</table>
4 Implementation
This guideline is applicable to all Queensland public and private maternity facilities. It can be downloaded in Portable Document Format (PDF) from www.health.qld.gov.au/qcg.

4.1 Guideline resources
The following guideline components are provided on the website as separate resources:
- Flowchart: Hypoglycaemia-newborn–Preventative care of the well at risk (for hypoglycaemia) newborn baby
- Flowchart: Hypoglycaemia-newborn–Management of hypoglycaemic newborn baby (BGL 1.5 mmol/L–2.5 mmol/L)
- Flowchart: Hypoglycaemia-newborn–Management of neonatal hypoglycaemia (baby symptomatic or BGL < 1.5 mmol/L)
- Education resource: Hypoglycaemia-newborn
- Knowledge assessment: Hypoglycaemia-newborn
- Parent information: Hypoglycaemia in a newborn baby

4.2 Suggested resources
During the development process stakeholders identified additional resources with potential to complement and enhance guideline implementation and application. The following resources have not been sourced or developed by QCG but are suggested as complimentary to the guideline:
- Procedures and protocols on blood sampling from babies

4.3 Implementation measures
4.3.1 Implications for implementation
The following areas may have implications for local implementation of the guideline recommendations. It is suggested they be considered for successful guideline implementation.
- Economic considerations including opportunity costs
- Human resource requirements including clinician skill mix and scope of practice
- Clinician education and training
- Equipment and consumables purchase and maintenance
- Consumer acceptance
- Model of care and service delivery

Suggested activities to assist implementation of the guideline are outlined below.

4.3.2 QCG measures
- Notify Chief Executive Officer and relevant stakeholders
- Monitor emerging new evidence to ensure guideline reflects contemporaneous practice
- Capture user feedback
- Record and manage change requests
- Review guideline in 2024

4.3.3 Hospital and Health Service measures
Initiate, promote and support local systems and processes to integrate the guideline into clinical practice, including:
- Hospital and Health Service (HHS) Executive endorse the guidelines and their use in the HHS and communicate this to staff
- Promote the introduction of the guideline to relevant health care professionals
- Support education and training opportunities relevant to the guideline and service capabilities
- Align clinical care with guideline recommendations
- Undertake relevant implementation activities as outlined in the Guideline implementation checklist available at www.health.qld.gov.au/qcg
4.4 Quality measures

Auditing of guideline recommendations and content assists with identifying quality of care issues and provides evidence of compliance with the National Safety and Quality Health Service (NSQHS) Standards [Refer to Table 9. NSQHS Standard 1]. Suggested audit and quality measures are identified in Table 10. Clinical quality measures.

Table 9. NSQHS Standard 1

<table>
<thead>
<tr>
<th>NSQHS Standard 1: Clinical governance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical performance and effectiveness</td>
</tr>
<tr>
<td>Criterion 1.27: Actions required:</td>
</tr>
<tr>
<td>Evidence based care</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

The following clinical quality measures are suggested:

Table 10. Clinical quality measures

<table>
<thead>
<tr>
<th>No</th>
<th>Audit criteria</th>
<th>Guideline Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Compliance with local protocols for calibration checks of bedside glucometers</td>
<td>3.1 Table 5</td>
</tr>
<tr>
<td>2.</td>
<td>Number of at risk babies screened for hypoglycaemia before second feed not later than 3 hours of age</td>
<td>3.1 Table 5</td>
</tr>
<tr>
<td>3.</td>
<td>Number of glucometer screenings less than 2.6 mmol/L confirmed by validated test</td>
<td>3.1 Table 5</td>
</tr>
<tr>
<td>4.</td>
<td>Percentage of babies with transient hypoglycaemia (1.5 mmol–2.5 mmol/L) treated with glucose gel 40% and feed</td>
<td>4.3 Table 9</td>
</tr>
<tr>
<td>5.</td>
<td>Number of babies with relevant history given a six hour fast test</td>
<td>6.6 Table 20</td>
</tr>
</tbody>
</table>

4.5 Areas for future research

During development some areas where identified as having limited or poor quality evidence to inform clinical decision making. Further research in these areas may be useful.
4.6 Safety and quality

Implementation of this guideline provides evidence of compliance with the National Safety and Quality Health Service Standards and Australian Council on Healthcare Standards (ACHS).²

Table 11. NSQHS/EQuIP National Criteria

<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>Evidence of compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSQHS Standard 1: Clinical governance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Patient safety and quality systems</strong></td>
<td>Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.</td>
<td>Diversity and high risk groups 1.15 The health service organisation: a. Identifies the diversity of the consumers using its services b. Identifies groups of patients using its services who are at higher risk of harm c. Incorporates information on the diversity of its consumers and higher-risk groups into the planning and delivery of care</td>
</tr>
<tr>
<td><strong>Clinical performance and effectiveness</strong></td>
<td>The workforce has the right qualifications, skills and supervision to provide safe, high-quality health care to patients.</td>
<td>Evidence based care 1.27 The health service organisation has processes that: a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care</td>
</tr>
<tr>
<td><strong>Performance management</strong></td>
<td>The health service organisation has valid and reliable performance review processes that: a. Require members of the workforce to regularly take part in a review of their performance b. Identify needs for training and development in safety and quality c. Incorporate information on training requirements into the organisation's training system</td>
<td></td>
</tr>
<tr>
<td><strong>Patient safety and quality systems</strong></td>
<td>Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.</td>
<td>Policies and procedures 1.7 The health service organisation uses a risk management approach to: a. Set out, review, and maintain the currency and effectiveness of, policies, procedures and protocols b. Monitor and take action to improve adherence to policies, procedures and protocols c. Review compliance with legislation, regulation and jurisdictional requirements</td>
</tr>
<tr>
<td>NSQHS Criteria</td>
<td>Actions required</td>
<td>Evidence of compliance</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>NSQHS Standard 2: Partnering with Consumers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Health literacy</strong></td>
<td>Health service organisations communicate with consumers in a way that supports effective partnerships.</td>
<td></td>
</tr>
<tr>
<td><strong>Partnersing with consumers in organisational design and governance</strong></td>
<td>Consumers are partners in the design and governance of the organisation.</td>
<td></td>
</tr>
<tr>
<td><strong>NSQHS Standard 4: Medication safety</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical governance and quality improvement to support medication management</strong></td>
<td>Organisation-wide systems are used to support and promote safety for procuring, supplying, storing, compounding, manufacturing, prescribing, dispensing, administering and monitoring the effects of medicines</td>
<td></td>
</tr>
<tr>
<td><strong>Integrating clinical governance</strong></td>
<td>Clinicians use the safety and quality systems from the Clinical Governance Standard when:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Implementing policies and procedures for medication management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Managing risks associated with medication management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. Identifying training requirements for medication management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The guideline provides current evidence based recommendations about medication</td>
<td></td>
</tr>
</tbody>
</table>

- Consumer consultation was sought and obtained during the development of the guideline. Refer to the acknowledgement section of the guideline for details
- Consumer information is developed to align with the guideline and included consumer involvement during development and review
- The consumer information was developed using plain English and with attention to literacy and ease of reading needs of the consumer
- Consumers are members of guideline working parties
- The guideline is based on the best available evidence
- The guidelines and consumer information are endorsed by the QCG and Queensland Statewide Maternity and Neonatal Clinical Network Steering Committees which includes consumer membership
## NSQHS Standard 5: Comprehensive care

<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>☑️ Evidence of compliance</th>
</tr>
</thead>
</table>
| Clinical governance and quality improvement to support comprehensive care | Integrating clinical governance  
5.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:  
a. Implementing policies and procedures for comprehensive care  
b. Managing risks associated with comprehensive care  
c. Identifying training requirements to deliver comprehensive care  
Partnering with consumers  
5.3 Clinicians use organisational processes from the Partnering with Consumers Standard when providing comprehensive care to:  
a. Actively involve patients in their own care  
b. Meet the patient’s information needs  
c. Share decision-making | ☑️ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet [http://www.health.qld.gov.au/qcg](http://www.health.qld.gov.au/qcg)  
☑️ The guideline provides evidence-based and best practice recommendations for care  
☑️ Consumer information is developed for the guideline |

## NSQHS Standard 6: Communicating for safety

<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>☑️ Evidence of compliance</th>
</tr>
</thead>
</table>
| Clinical governance and quality improvement to support effective communication | Integrating clinical governance  
6.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:  
a. Implementing policies and procedures to support effective clinical communication  
b. Managing risks associated with clinical communication  
c. Identifying training requirements for effective and coordinated clinical communication  
Partnering with consumers  
6.3 Clinicians use organisational processes from the Partnering with Consumers Standard to effectively communicate with patients, carers and families during high-risk situations to:  
a. Actively involve patients in their own care  
b. Meet the patient’s information needs  
c. Share decision-making  
Organisational processes to support effective communication  
6.4 The health service organisation has clinical communications processes to support effective communication when:  
a. Identification and procedure matching should occur  
b. All or part of a patient’s care is transferred within the organisation, between multidisciplinary teams, between clinicians or between organisations; and on discharge  
c. Critical information about a patient’s care, including information on risks, emerges or changes | ☑️ Requirements for effective clinical communication by clinicians are identified  
☑️ The guideline provides evidence-based and best practice recommendations for communication between clinicians  
☑️ The guideline provides evidence-based and best practice recommendations for communication with patients, carers and families  
☑️ The guideline provides evidence-based and best practice recommendations for discharge planning and follow-up care |
<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>Evidence of compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSQHS Standard 6: Communicating for safety (continued)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Communication of critical information</strong></td>
<td>Systems to effectively communicate critical information and risks when they emerge or change are used to ensure safe patient care.</td>
<td><strong>Communicating critical information</strong>&lt;br&gt;6.9 Clinicians and multidisciplinary teams use clinical communication processes to effectively communicate critical information, alerts and risks, in a timely way, when they emerge or change to:&lt;br&gt;a. Clinicians who can make decisions about care&lt;br&gt;b. Patients, carers and families, in accordance with the wishes of the patient&lt;br&gt;6.10 The health service organisation ensures that there are communication processes for patients, carers and families to directly communicate critical information and risks about care to clinicians&lt;br&gt;☐ Requirements for effective clinical communication of critical information are identified&lt;br&gt;☐ Requirements for escalation of care are identified</td>
</tr>
<tr>
<td><strong>Correct identification and procedure matching</strong></td>
<td>Systems to maintain the identity of the patient are used to ensure that the patient receives the care intended for them.</td>
<td><strong>Correct identification and procedure matching</strong>&lt;br&gt;6.5 The health service organisation:&lt;br&gt;a. Defines approved identifiers for patients according to best-practice guidelines&lt;br&gt;b. Requires at least three approved identifiers on registration and admission; when care, medication, therapy and other services are provided; and when clinical handover, transfer or discharge documentation is generated&lt;br&gt;☐ Requirements for safe and for correct patient identification are identified</td>
</tr>
<tr>
<td><strong>Communicating at clinical handover</strong></td>
<td>Processes for structured clinical handover are used to effectively communicate about the health care of patients.</td>
<td><strong>Clinical handover</strong>&lt;br&gt;6.7 The health service organisation, in collaboration with clinicians, defines the:&lt;br&gt;a. Minimum information content to be communicated at clinical handover, based on best-practice guidelines&lt;br&gt;b. Risks relevant to the service context and the particular needs of patients, carers and families&lt;br&gt;c. Clinicians who are involved in the clinical handover&lt;br&gt;6.8 Clinicians use structured clinical handover processes that include:&lt;br&gt;a. Preparing and scheduling clinical handover&lt;br&gt;b. Having the relevant information at clinical handover&lt;br&gt;c. Organising relevant clinicians and others to participate in clinical handover&lt;br&gt;d. Being aware of the patient’s goals and preferences&lt;br&gt;e. Supporting patients, carers and families to be involved in clinical handover, in accordance with the wishes of the patient&lt;br&gt;f. Ensuring that clinical handover results in the transfer of responsibility and accountability for care&lt;br&gt;☐ The guideline acknowledges the need for local protocols to support transfer of information, professional responsibility and accountability for some or all aspects of care</td>
</tr>
<tr>
<td>NSQHS Criteria</td>
<td>Actions required</td>
<td>☑ Evidence of compliance</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>NSQHS Standard 7: Blood management</strong></td>
<td><strong>Integrating clinical governance</strong></td>
<td></td>
</tr>
<tr>
<td>Clinical governance and quality improvement to support blood management</td>
<td>7.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:</td>
<td>☑ The guideline provides evidence-based and best practice recommendations for use of blood products</td>
</tr>
<tr>
<td>Organisation-wide governance and quality improvement systems are used</td>
<td>a. Implementing policies and procedures for blood management</td>
<td></td>
</tr>
<tr>
<td>to ensure safe and high-quality care of patients’ own blood, and to ensure</td>
<td>b. Managing risks associated with blood management</td>
<td></td>
</tr>
<tr>
<td>that blood product requirements are met.</td>
<td>c. Identifying training requirements for blood management</td>
<td></td>
</tr>
<tr>
<td><strong>Prescribing and clinical use of blood and blood products</strong></td>
<td><strong>Optimising and conserving patients’ own blood</strong></td>
<td></td>
</tr>
<tr>
<td>The clinical use of blood and blood products is appropriate, and strategies</td>
<td>7.4 Clinicians use the blood and blood products processes to manage the need for, and minimise the inappropriate use</td>
<td>☑ The guideline provides evidence-based and best practice recommendations for use of blood products</td>
</tr>
<tr>
<td>are used to reduce the risks associated with transfusion.</td>
<td>of, blood and blood products by:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Optimising patients’ own red cell mass, haemoglobin and iron stores</td>
<td>☑ The guideline is consistent with recommendations of national guidelines</td>
</tr>
<tr>
<td></td>
<td>b. Identifying and managing patients with, or at risk of, bleeding</td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. Determining the clinical need for blood and blood products, and related risks</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Prescribing and administering blood and blood products</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.6 The health service organisation supports clinicians to prescribe and administer blood and blood products</td>
<td></td>
</tr>
<tr>
<td></td>
<td>appropriately, in accordance with national guidelines and national criteria</td>
<td></td>
</tr>
</tbody>
</table>
## NSQHS Criteria

**NSQHS Standard 8: Recognising and responding to acute deterioration**

<table>
<thead>
<tr>
<th>NSQHS Criteria</th>
<th>Actions required</th>
<th>Evidence of compliance</th>
</tr>
</thead>
</table>
| **Clinical governance and quality improvement to support recognition and response systems** | Integrating clinical governance  
8.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when:  
a. Implementing policies and procedures for recognising and responding to acute deterioration  
b. Managing risks associated with recognising and responding to acute deterioration  
c. Identifying training requirements for recognising and responding to acute deterioration  
Partnering with consumers  
8.3 Clinicians use organisational processes from the Partnering with Consumers Standard when recognising and responding to acute deterioration to:  
a. Actively involve patients in their own care  
b. Meet the patient's information needs  
c. Share decision-making  
Recognising acute deterioration  
8.4 The health service organisation has processes for clinicians to detect acute physiological deterioration that require clinicians to:  
a. Document individualised vital sign monitoring plans  
b. Monitor patients as required by their individualised monitoring plan  
c. Graphically document and track changes in agreed observations to detect acute deterioration over time, as appropriate for the patient | ☑ The guideline is consistent with National Consensus statements recommendations  
☑ The guideline recommends use of tools consistent with the principles of recognising and responding to clinical deterioration  
☑ Consumer information is developed for the guideline |

Organisation-wide systems are used to support and promote detection and recognition of acute deterioration, and the response to patients whose condition acutely deteriorates.
5 References